Compare Organon & Co. Common Stock (OGN) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Shopify Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Shopify Inc. trades at $169.06 (market cap $227.12B). The key difference: Shopify Inc. is far larger — about 62.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Shopify Inc. for 78 Days on average.
| OGN | SHOP | |
|---|---|---|
Market Cap | $3.62B | $227.12B |
Volume | 2,892,999 | 6,965,160 |
Sector | Health | Technology |
52-Week High | $13.81 | $179.22 |
52-Week Low | $5.70 | $95.40 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $11.04B | $222.35B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SHOP trades at $172.50, down 3.75% today but maintains a bullish technical outlook with strong moving average support. The company shows robust revenue growth from $5.6B in 2022 to $11.6B in 2025, though valuation ratios remain elevated with a P/E of 119.27. Recent news highlights Shopify's AI innovations including Canvas site-building tool and open AI agent checkout, positioning it favorably against competitors.
Shopify's outlook remains positive with 67% analyst buy ratings and $172.47 consensus target. Key opportunities include AI-driven commerce expansion and merchant solutions growth accelerating to 37%. Risks include high valuation multiples and competitive pressure from Amazon's opposing AI strategy. The stock offers growth potential but requires monitoring of earnings sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
